Alpha1-Proteinase Inhibitor

Table of contents

  • Brand Names
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Prolastin; Denmark: Prolastina; France: Alfalastin; Germany: Prolastin; Ireland: Prolastin; Italy: Prolastina; Netherlands: Prolastin; Poland: Prolastin; Portugal: Prolastin; Spain: Prolastina; Sweden: Prolastina.

North America

Canada: Prolastin; USA: Aralast, Prolastin, Zemaira.

Latin America

Argentina: Prolastín, Trypsan.

Drug combinations


Pharmacologic Category

Antihemorrhagic Agents; Proteinase Inhibitors. (ATC-Code: B02AB).

Mechanism of action

Serum protease inhibitor. Inactivates proteolytic enzymes (secreted during inflammation).

Therapeutic use

Replacement therapy in congenital α~1~-antitrypsin deficiency with clinical emphysema.

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to any component of the formulation or alpha~1~-proteinase inhibitor products. Selective IgA deficiency with known anti-IgA antibody.

Warnings and precautions

Hypersensitivity and anaphylactic reactions may occur in patients with anti-IgA antibody. Hepatitis B (consider immunization). Product of human plasma (may contain infectious agents). Use with caution in patients at risk for fluid overload.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart